Payment overview · 2025
General Payments
$1,956.00
106 reported records · 21 companies
Healthcare provider profile · identity verified
Eric J Betts, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LA FAYETTE, GA · NPI 1336132679
Verified facts
What the public records show
CMS Open Payments records show Eric J Betts, M.D. received $1,956.00 in general payments during 2025 across 106 reported records.
ABBVIE INC. accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $277.28 | 14.2% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $220.46 | 11.3% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $220.04 | 11.2% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $189.92 | 9.7% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $179.30 | 9.2% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $148.95 | 7.6% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $100.02 | 5.1% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $98.24 | 5.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $82.80 | 4.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $82.43 | 4.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $78.00 | 4.0% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $50.99 | 2.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.55 | 1.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.46 | 1.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.26 | 1.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.00 | 1.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.95 | 1.2% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $17.77 | 0.9% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.35 | 0.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.17 | 0.7% | 1 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $14.06 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,956.00 | 106 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $272.72 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $206.55 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $183.43 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $141.84 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $141.81 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $101.79 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $100.02 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $93.54 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $82.43 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.04 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $78.00 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.84 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $69.82 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $66.36 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.59 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $59.16 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $59.16 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $59.16 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $56.63 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $54.89 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $50.99 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $37.55 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.26 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.23 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.14 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 112 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 107 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
107 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 28 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 814 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 515 | 131 |
| Lisinopril | Lisinopril | 440 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 105 |
| Gabapentin | Gabapentin | 343 | 81 |
| Omeprazole | Omeprazole | 343 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 259 | 75 |
| Metformin Hcl | Metformin Hcl | 246 | 77 |
| Losartan Potassium | Losartan Potassium | 195 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 52 |
| Montelukast Sodium | Montelukast Sodium | 173 | 47 |
| Carvedilol | Carvedilol | 172 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 47 |
| Meloxicam | Meloxicam | 159 | 38 |
| Furosemide | Furosemide | 157 | 44 |
| Trazodone Hcl | Trazodone Hcl | 152 | 38 |
| Potassium Chloride | Potassium Chloride | 148 | 46 |
| Buspirone Hcl | Buspirone Hcl | 141 | 36 |
| Clonazepam | Clonazepam | 132 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 130 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 32 |
| Alendronate Sodium | Alendronate Sodium | 118 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 28 |
| Eliquis | Apixaban | 112 | 28 |
| Sertraline Hcl | Sertraline Hcl | 112 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 45 |
| Tramadol Hcl | Tramadol Hcl | 107 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 15 |
| Simvastatin | Simvastatin | 99 | 27 |
| Famotidine | Famotidine | 98 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 22 |
| Allopurinol | Allopurinol | 97 | 29 |
| Jardiance | Empagliflozin | 91 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 25 |
| Mirtazapine | Mirtazapine | 86 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 80 | 20 |
| Glimepiride | Glimepiride | 80 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 20 |
| Metformin Hcl Er | Metformin Hcl | 74 | 18 |
| Pregabalin | Pregabalin | 74 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 19 |
| Lorazepam | Lorazepam | 59 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 11 |
| Alprazolam | Alprazolam | 56 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 53 | 13 |
| Spironolactone | Spironolactone | 53 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Januvia | Sitagliptin Phosphate | 52 | 12 |
| Celecoxib | Celecoxib | 51 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 15 |
| Donepezil Hcl | Donepezil Hcl | 50 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 11 |
| Ozempic | Semaglutide | 48 | 13 |
| Promethazine Hcl | Promethazine Hcl | 47 | 11 |
| Ibuprofen | Ibuprofen | 46 | 15 |
| Dutasteride | Dutasteride | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Ezetimibe | Ezetimibe | 44 | 11 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Valsartan | Valsartan | 42 | 11 |
| Farxiga | Dapagliflozin Propanediol | 41 | 15 |
| Prednisone | Prednisone | 41 | 36 |
| Diazepam | Diazepam | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 11 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 30 |
| Ondansetron Odt | Ondansetron | 31 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 12 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 23 |
| Topiramate | Topiramate | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 11 |
| Estradiol | Estradiol | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 17 |
| Naproxen | Naproxen | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,956.00 · 106 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, Evoke, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, MOUNJARO, NP Thyroid 60, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, Symbravo, TONMYA, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error